KEYMED BIO-B_Providing professional financial news and data related to KEYMED BIO-B, committed to creating a comprehensive and efficient information access channel for users | NewTimeSpace

KEYMED BIO-B (02162.HK): Non-Executive Director Dr. Wang Minchuan Resigns, Effective 4 September 2026

Tags：

KEYMED BIO-B 02162.HK

2026-09-07

KEYMED BIO-B (02162.HK): Exclusive License Agreement for Stapokibart Covering 18 Countries and Regions Including Southeast Asia and Central Asia

Tags：

KEYMED BIO-B 02162.HK Licensing

2026-09-02

KEYMED BIO-B(02162.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 1.22 billion, turned profitable from a loss YoY

Tags：

KEYMED BIO-B 02162.HK turned profitable from loss

2026-08-20

KEYMED BIO-B (02162.HK): Proposes RMB Share Issuance and STAR Market Listing on Shanghai Stock Exchange, Subject to Shareholder and Regulatory Approvals

Tags：

KEYMED BIO-B 02162.HK A+H

2026-08-19

KEYMED BIO-B (02162.HK): Phase II trial of CM512 (TSLP x IL-13 bispecific antibody) for chronic rhinosinusitis with nasal polyps meets all study endpoints; Phase III to advance with 300mg once-half-yearly regimen

Tags：

KEYMED BIO-B 02162.HK R&D Progress

2026-08-10

KEYMED BIO-B (02162.HK): Global Phase III Trial of CMG901 (AZD0901) Meets Primary Endpoint, Delivers Improved OS for 2L+ Gastric Cancer; AstraZeneca Forecasts Peak Sales of USD3-5 Billion

Tags：

KEYMED BIO-B 02162.HK AstraZeneca Clinical Trial

2026-07-28

KEYMED BIO-B (02162.HK): CM512 (TSLP/IL-13 Bispecific Antibody) Granted Breakthrough Therapy Designation by NMPA

Tags：

KEYMED BIO-B 02162.HK CDE Breakthrough Therapy

2026-07-23

Scan QR Code

Download App